Bictegravir/lenacapavir (Bixlenvo) vs Cabotegravir (Apretude)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Bictegravir/lenacapavir (Bixlenvo)
Marketed by Gilead Sciences
NCT05502341 · Phase 2/3 · active, not recruiting
This was a randomized, active-controlled trial in 557 people in its Phase 3 part, but it was open-label, so participants and investigators knew which treatment each person received. Its primary endpoint, the proportion with detectable HIV-1 RNA at week 48, is an objective laboratory measure, and bictegravir/lenacapavir met the non-inferiority goal against continued complex regimens.
Next expected readout: July 2028 · NCT07908446 (registry estimate)
Reported efficacy
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm; Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). (met)
Result source: NCT05502341
Cabotegravir (Apretude)
Marketed by GlaxoSmithKline
NCT02720094 · Phase 2/3 · completed
The trial randomized 4,570 participants to cabotegravir or active-controlled TDF/FTC treatment and used quadruple blinding of participants, clinicians, investigators, and outcome assessors. Its hard clinical primary efficacy endpoint—documented incident HIV infection—was met, with 13 versus 39 infections and a hazard ratio of 0.340 (95% CI 0.18–0.62; p=0.0005).
Next expected readout: August 2028 · NCT06474364 (registry estimate)
Reported efficacy
Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.); Number of Participants Experiencing Grade 2 or Higher Clinical and Laboratory Adverse Events (Treatment emergent AE* measured with onset date through participant's last study visit, or the date of DSMB decision to unblind all participants, whichever is earliest. Assessed at each visit (injections visits q 8 weeks and safety visits q 8 weeks).): Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.): Cabotegravir 13/2280 vs TDF/FTC 39/2281 (met)
Result source: NCT02720094
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bictegravir/lenacapavir (Bixlenvo) | Cabotegravir (Apretude) |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Trial running · NCT06532656 | —Trial running · NCT06133686 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT06532656 | —Trial running · NCT06133686 |
| CD4 count, change (week 48) | —Trial running · NCT06532656 | —Trial running · NCT06133686 |
HIV-1 RNA below 50 copies/mL (week 48)
- Bictegravir/lenacapavir (Bixlenvo)
- —Trial running · NCT06532656
- Cabotegravir (Apretude)
- —Trial running · NCT06133686
HIV-1 RNA 50 copies/mL or more (week 48)
- Bictegravir/lenacapavir (Bixlenvo)
- —Trial running · NCT06532656
- Cabotegravir (Apretude)
- —Trial running · NCT06133686
CD4 count, change (week 48)
- Bictegravir/lenacapavir (Bixlenvo)
- —Trial running · NCT06532656
- Cabotegravir (Apretude)
- —Trial running · NCT06133686
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir/lenacapavir (Bixlenvo)'s landscape · Cabotegravir (Apretude)'s landscape